RbAp48
- Known as:
- RbAp48
- Catalog number:
- 50297
- Product Quantity:
- 50 µg
- Category:
- -
- Supplier:
- BPS Bioscience
- Gene target:
- RbAp48
Related genes to: RbAp48
- Gene:
- RBBP4 NIH gene
- Name:
- RB binding protein 4, chromatin remodeling factor
- Previous symbol:
- -
- Synonyms:
- RbAp48, NURF55, lin-53
- Chromosome:
- 1p35.1
- Locus Type:
- gene with protein product
- Date approved:
- 1995-05-05
- Date modifiied:
- 2016-05-25
Related products to: RbAp48
Related articles to: RbAp48
- Colorectal cancer (CRC) is one of the most common malignancies worldwide. Early and accurate diagnosis remains a clinical priority, yet current biopsy techniques are invasive, spatially limited, and may not capture the molecular heterogeneity of tumors. We evaluated the feasibility and diagnostic potential of electroporation-based biopsy (e-biopsy) as a minimally invasive technique for proteomic sampling of colorectal cancer tissues. We conducted a multicenter, multinational study involving 19 patients undergoing surgical resection for CRC. Paired tumor and adjacent normal tissues were sampled ex vivo using e-biopsy. Proteins extracted from each sample were analyzed via LC-MS/MS. Bioinformatics pipelines, including differential expression, PCA, and pathway analysis, were used to identify CRC-specific signatures. E-biopsy consistently retrieved more proteins from tumor tissues than from adjacent healthy tissues (mean: 1300 vs. 800). Of the 3246 proteins identified, 54% were significantly upregulated in tumor tissues. Notably, proteins such as DLAT, LETM1, RBBP4, PPIB, and BCAP31 emerged as potential CRC biomarkers. Functional analyses revealed dysregulation in RNA processing, immune response, and metabolic pathways, consistent with known CRC biology. The integrated workflow, spanning tissue collection, electroporation, protein isolation, and mass spectrometry analysis across four institutions in two countries, was successfully executed, demonstrating the feasibility of multi-institutional implementation of the e-biopsy protocol while preserving tissue integrity throughout. E-biopsy enables rapid, reproducible, and minimally invasive molecular sampling of CRC tissue. This study demonstrates its potential to complement standard histopathology, aid in early diagnosis, and support molecularly guided treatment strategies in colorectal oncology. - Source: PubMed
Saulis GintautasVitkin EdwardSaule RitaWise JuliaGulbinas AntanasDambrauskas ŽilvinasIvanauskienė SandraŽilinskas JustasPoskiene LinaGolberg Alexander - Breast cancer (BC) is the second leading cause of cancer-related deaths worldwide and has a high recurrence rate. This study aimed to evaluate the expression levels of three biomarkers: DNA methyltransferase 1 (DNMT1), histone deacetylase 1 (HDAC1), and metallothionein 1E (MT1E) in BC patients. - Source: PubMed
Akhtartavan SedighehMadanchi HamidGhorbani RahebKhalafi-Nezhad AbolfazlAbdullahi AhmadShamsi FahimehHeli Hossein - Polycomb repressive complex 2 (PRC2) silences MHC class I antigen presentation across cancer types, yet the role of its core scaffolding subunit SUZ12 in pancreatic ductal adenocarcinoma (PDAC) immune phenotypes remains poorly characterized. - Source: PubMed
Publication date: 2026/06/23
Wang ZhuoxinJin ChenyangYin FeiWu XuejiaoYang Zilin - Upstream regulators of the homologous recombination (HR) repair pathway are promising targets for overcoming temozolomide (TMZ) resistance. We investigated whether pharmacologic inhibition of Retinoblastoma Binding Protein 4 (RBBP4)/p300-mediated HR activity by CCS1477 or NEO2734 sensitizes glioblastoma (GBM) to TMZ. - Source: PubMed
Publication date: 2026/05/29
Mapunda Josephine ALaverty Daniel JAziz FaisalLe AnSangare JunitaZhang LinNagel Zachary DFrench Jarrod BSarkaria Jann NKitange Gaspar J - Photodynamic therapy, as an efficient and safe method, has attracted the attention of experts. This therapeutic method is based on the application of photosensitizers and light radiation. This study was designed to assess the possible molecular mechanism of rhodium nanoparticle-based photodynamic therapy through protein-protein interaction (PPI) network analysis of proteomic data from the literature. Proteomic data about rhodium nanoparticle-based photodynamic therapy effect on the HeLa cell line proteome were retrieved from the literature and were included in the CluePedia application of Cytoscape software to create a directed PPI network. The network was analyzed, and the crucial targeted proteins were identified and compared with genes in GeneCards for "HeLa cell line" and "cervical cancer". The common gene and protein were selected and discussed. A directed PPI network of 105 proteins was formed. Six sub-networks were selected for further investigation. Comparison of the PPI data and the genes from the GeneCards database led to the introduction of HLA-B, CYCS, CD44, HSPB1, and RBBP4 as the critical targeted proteins by the applied treatment. In conclusion, a sub-network including HLA-B, CYCS, CD44, and HSPB1 and another sub-network containing RBBP4 and its neighbors were highlighted as the core of molecular effects of the applied rhodium nanoparticle-based photodynamic therapy. - Source: PubMed
Publication date: 2026/04/22
Hossein-Khannazer NikooArjmand BabakRazzaghi ZahraRazi FaridehBandarian FatemehAhmadzadeh Alireza